Abstract | UNLABELLED: METHODS: Thirty-four HCC patients undergoing 78 (18)F-fluoroethylcholine PET/CT scans were identified for this study. Patients with initial or follow-up metastastic disease (n = 9) were excluded at the time point of the metastatic occurrence as well as patients with negative α- fetoprotein (AFP; n = 1), resulting in 24 patients and 57 scans that were eligible. All patients were scheduled for radioembolization and underwent 1 pretherapeutic and at least 1 posttherapeutic (18)F-fluoroethylcholine PET/CT scan. Volume-of-interest analysis and volume-of-interest subtractions were performed. Maximum, mean, and peak standardized uptake value (SUV) analysis was performed, and the total intrahepatic (18)F-fluoroethylcholine positive tumor volume (FEC-PTV) and tumor-to-background ratio were assessed. Statistical analysis was performed using a decreasing AFP of at least 20% as a standard of reference for therapy response including receiver-operating-characteristic analyses as well as descriptive and correlation analyses and multiple logistic regression. RESULTS: Fourteen follow-up examinations were categorized as responder and 19 follow-up examinations as nonresponder. Absolute AFP values did not correlate with SUV parameters (P = 0.055). In receiver-operating-characteristic analyses, the initial mean SUV, Δmaximum SUV, and Δtumor-to-background ratio demonstrated the highest area under the curve, 0.84 (P = 0.009), 0.83 (P = 0.011), and 0.83 (P = 0.012), respectively, resulting in a positive prediction of 82%, 83%, and 91% at the respective cutoff points. When multiple logistic regression analysis was applied, this resulted in an area under the curve of 0.90 (P = 0.001), with a positive prediction of 94% and a sensitivity of 94%. The FEC-PTV did not reach significance in the presented dataset. CONCLUSION:
(18)F-fluoroethylcholine PET/CT demonstrates a high potential for follow-up assessment in the context of radioembolization in patients with locally advanced, but nonmetastatic, HCC and initially elevated AFP, possibly enabling early therapy monitoring independent of morphology.
|
Authors | Markus Hartenbach, Stefan Weber, Nathalie L Albert, Sabrina Hartenbach, Albert Hirtl, Mathias J Zacherl, Philipp M Paprottka, Reinhold Tiling, Peter Bartenstein, Marcus Hacker, Alexander R Haug |
Journal | Journal of nuclear medicine : official publication, Society of Nuclear Medicine
(J Nucl Med)
Vol. 56
Issue 11
Pg. 1661-6
(Nov 2015)
ISSN: 1535-5667 [Electronic] United States |
PMID | 26405170
(Publication Type: Journal Article)
|
Copyright | © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc. |
Chemical References |
- Radiopharmaceuticals
- alpha-Fetoproteins
- fluoroethylcholine
- Choline
|
Topics |
- Carcinoma, Hepatocellular
(diagnostic imaging, therapy)
- Choline
(analogs & derivatives)
- Embolization, Therapeutic
(methods)
- Humans
- Liver Neoplasms
(diagnostic imaging, therapy)
- Positron-Emission Tomography
- Predictive Value of Tests
- ROC Curve
- Radiopharmaceuticals
- Retrospective Studies
- Treatment Outcome
- alpha-Fetoproteins
|